Business Context and Reporting Period
This Form 8-K Current Report was filed by Immuneering Corporation on June 11, 2026. The filing discloses the appointment of a new Chief Financial Officer and Treasurer, effective upon the commencement of employment expected on or before July 16, 2026.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change is the appointment of Andrew Gengos as Chief Financial Officer and Treasurer, succeeding Mallory Morales in the role of principal financial officer. Ms. Morales will continue as Senior Vice President Finance and Chief Accounting Officer.
Guidance, Outlook, and Compensation Details
The filing outlines the compensation package for Mr. Gengos, which serves as a material inducement for his employment:
- Base Salary: $530,000 annually.
- Performance Bonus: Target discretionary annual bonus of 40% of base salary.
- Equity Award: Option to purchase 650,000 shares of Class A common stock under the 2025 Employment Inducement Award Plan.
- Severance Provisions:
- Termination without "cause" or resignation for "good reason" triggers 12 months of base salary continuation, unpaid prior year bonus, and COBRA premium reimbursement.
- Qualifying termination within 12 months of a change in control adds a payment equal to 1.0 times the target annual bonus and accelerated vesting of equity awards.
Forward-looking statements regarding the timing of employment and equity grants are subject to inherent uncertainties and risks detailed in the Company's Form 10-Q filed on May 15, 2026.
Investor Verification Checklist
- Verify the actual commencement date of Mr. Gengos' employment to confirm the "Effective Date" for financial officer designation.
- Confirm the final grant date and terms of the 650,000 share option award once employment begins.
- Review the Company's Form 10-Q for the period ended March 31, 2026, for updated risk factors affecting the company's outlook.
- Monitor future filings for any changes to the compensation structure or additional executive appointments.